New combo aims to turn untreatable lung tumors into surgical candidates
NCT ID NCT07561983
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 2 trial tests whether combining the immunotherapy drug tislelizumab with standard chemotherapy and a targeted chemo-blocking procedure (BACE) can shrink advanced, inoperable stage III non-small cell lung cancer enough to allow surgery. About 39 participants will receive up to 4 cycles of the triple therapy. If their tumors become operable, they may undergo surgery; if not, they will receive standard chemoradiotherapy. The main goal is to see how many patients remain cancer-free after one year.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Tislelizumab (an immunotherapy drug) combined with intravenous chemotherapy and a procedure called bronchial artery chemoembolization (BACE)
- What this could lead to
- If successful, this approach could shrink inoperable lung tumors enough to allow surgery, potentially improving long-term survival.
- What could go wrong
- This is a small, early-phase trial (39 people) with no control group. The combination may cause significant side effects, and not all participants will become eligible for surgery.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHEMOEMBOLIZATION, THERAPEUTIC are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Sichuan Cancer Hospital and Research Institute
Chengdu, Sichuan, 610041, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could essential oils tame chemo nausea? a new trial puts aromatherapy to the test
- Shielding the ovaries: a drug may help young breast cancer patients preserve fertility during chemo
- Can surgery for stomach or esophageal cancer cloud the mind?
- Art therapy meets oncology: could mandala coloring boost cancer Patients' well-being?
- Could a chemo boost after radiation tame aggressive prostate cancer?
- Can a targeted drug combo boost chemoradiation in EGFR-Positive lung cancer?